MEDINET Co., Ltd.
TTSE:237022.00
JPY
0.00
(0.00%)
ISIN
JP3920990003
Return %
Stock
S&P 500
1Y
-38.89
14.20
3Y
-53.19
81.12
5Y
-66.15
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Kanenao Kubushiro
- Full Time Employees
- 107
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- TRC Center Building Tokyo TY Japan 143-0006
- IPO Date
- Oct 8, 2003
- Website
- medinet-inc.co.jp
- Similar Companies
- Business
- MEDINET Co., Ltd. (2370.T) engages primarily in the cell processing industry and cellular medical products business as a contract development and manufacturing organization providing comprehensive regenerative medicine and cell therapy solutions in Japan. The company offers manufacturing of regenerative medical products, investigational products, and specified cell products encompassing somatic cells such as CAR-T and immuno-cells including NKT cells-activated dendritic cells, dendritic cells, NK-cells, gamma delta T-cells, alpha beta T-cells; somatic stem cells like endometrium, mesenchymal stem cells, hematopoietic stem cells; and induced pluripotent stem cells; alongside value chain solutions comprising personnel training, facility and equipment design, operations and management, standard operating procedures preparation, logistics network, information systems, purchasing and production management, quality management systems, quality control and assurance, technology transfer, and process development. Founded in 1995 and headquartered in Tokyo, MEDINET operates from its Shinagawa Cell Processing Facility and supports medical institutions, research institutions, and biopharmaceutical companies primarily in Japan with expertise in therapies such as NKT-cell therapy, dendritic cell vaccine therapy, NK-cell therapy, gamma delta T-cell therapy, alpha beta T-cell therapy, and CTL therapy. Recent developments include a strategic partnership with AGC Inc. in September 2024 to accelerate cell and gene therapy CDMO business in Japan; a licensing agreement with Stempeutics Research Pvt. Ltd. in October 2025 for the Stempeucel cell therapy targeting chronic thromboembolic pulmonary hypertension; initiation of NKT cell-activated dendritic cell processing technology provision in February 2023; and a market transition from Tokyo Stock Exchange Mothers to Growth in April 2022.